Soleno Therapeutics Statistics Share Statistics Soleno Therapeutics has 53.15M
shares outstanding. The number of shares has increased by 23.26%
in one year.
Shares Outstanding 53.15M Shares Change (YoY) 23.26% Shares Change (QoQ) 5.46% Owned by Institutions (%) 99.99% Shares Floating 44.87M Failed to Deliver (FTD) Shares 2,755 FTD / Avg. Volume 0.15%
Short Selling Information The latest short interest is 7.25M, so 13.64% of the outstanding
shares have been sold short.
Short Interest 7.25M Short % of Shares Out 13.64% Short % of Float 15.57% Short Ratio (days to cover) 3.3
Valuation Ratios The PE ratio is -10.27 and the forward
PE ratio is 19.33.
Soleno Therapeutics's PEG ratio is
-0.12.
PE Ratio -10.27 Forward PE 19.33 PS Ratio 0 Forward PS 7.9 PB Ratio 7.37 P/FCF Ratio -26.05 PEG Ratio -0.12
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Soleno Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 15.68,
with a Debt / Equity ratio of 0.22.
Current Ratio 15.68 Quick Ratio 15.68 Debt / Equity 0.22 Debt / EBITDA -0.3 Debt / FCF -0.76 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.53M Employee Count 115 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 19.3% in the
last 52 weeks. The beta is -2.75, so Soleno Therapeutics's
price volatility has been lower than the market average.
Beta -2.75 52-Week Price Change 19.3% 50-Day Moving Average 69.41 200-Day Moving Average 64.94 Relative Strength Index (RSI) 44.37 Average Volume (20 Days) 1,873,485
Income Statement
Revenue n/a Gross Profit n/a Operating Income -184.43M Net Income -175.85M EBITDA -173.63M EBIT -175.62M Earnings Per Share (EPS) -4.38
Full Income Statement Balance Sheet The company has 87.93M in cash and 52.83M in
debt, giving a net cash position of 35.1M.
Cash & Cash Equivalents 87.93M Total Debt 52.83M Net Cash 35.1M Retained Earnings -452.26M Total Assets 332.31M Working Capital 295.85M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -69.1M
and capital expenditures -218K, giving a free cash flow of -69.31M.
Operating Cash Flow -69.1M Capital Expenditures -218K Free Cash Flow -69.31M FCF Per Share -1.73
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields SLNO does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for SLNO is $110,
which is 85.8% higher than the current price. The consensus rating is "Buy".
Price Target $110 Price Target Difference 85.8% Analyst Consensus Buy Analyst Count 9
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Aug 26, 2022. It was a
backward
split with a ratio of 1:15.
Last Split Date Aug 26, 2022 Split Type backward Split Ratio 1:15
Scores Altman Z-Score 17.36 Piotroski F-Score 3
